Tags

Type your tag names separated by a space and hit enter

Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
J Clin Oncol. 2012 Nov 20; 30(33):4117-23.JC

Abstract

PURPOSE

Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL.

PATIENTS AND METHODS

Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD.

RESULTS

Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/μL. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%).

CONCLUSION

In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL.

Authors+Show Affiliations

Department of Hematology, Oncology and Palliative Care, Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Sanatoriumsplatz 2, 81545 Munich, Germany. marcus.hentrich@klinikum-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23045592

Citation

Hentrich, Marcus, et al. "Stage-adapted Treatment of HIV-associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 30, no. 33, 2012, pp. 4117-23.
Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117-23.
Hentrich, M., Berger, M., Wyen, C., Siehl, J., Rockstroh, J. K., Müller, M., Fätkenheuer, G., Seidel, E., Nickelsen, M., Wolf, T., Rieke, A., Schürmann, D., Schmidmaier, R., Planker, M., Alt, J., Mosthaf, F., Engert, A., Arasteh, K., & Hoffmann, C. (2012). Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30(33), 4117-23. https://doi.org/10.1200/JCO.2012.41.8137
Hentrich M, et al. Stage-adapted Treatment of HIV-associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. J Clin Oncol. 2012 Nov 20;30(33):4117-23. PubMed PMID: 23045592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. AU - Hentrich,Marcus, AU - Berger,Marcel, AU - Wyen,Christoph, AU - Siehl,Jan, AU - Rockstroh,Jürgen K, AU - Müller,Markus, AU - Fätkenheuer,Gerd, AU - Seidel,Elisabeth, AU - Nickelsen,Maike, AU - Wolf,Timo, AU - Rieke,Ansgar, AU - Schürmann,Dirk, AU - Schmidmaier,Ralf, AU - Planker,Manfred, AU - Alt,Jürgen, AU - Mosthaf,Franz, AU - Engert,Andreas, AU - Arasteh,Keikawus, AU - Hoffmann,Christian, Y1 - 2012/10/08/ PY - 2012/10/10/entrez PY - 2012/10/10/pubmed PY - 2013/3/7/medline SP - 4117 EP - 23 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 30 IS - 33 N2 - PURPOSE: Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL. PATIENTS AND METHODS: Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD. RESULTS: Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/μL. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%). CONCLUSION: In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/23045592/Stage_adapted_treatment_of_HIV_associated_Hodgkin_lymphoma:_results_of_a_prospective_multicenter_study_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2012.41.8137?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -